Brentuximab vedotin (solution)

Brentuximab vedotin (solution) (cAC10-vcMMAE) is an antibody-drug conjugate (ADC) comprising an anti-CD30 antibody and the cytotoxic agent Monomethyl auristatin E (MMAE) . The antibody portion is Brentuximab (HY-P99151), and the drug-linker conjugate for ADC is VcMMAE (HY-15575) . Brentuximab vedotin (solution) inhibits CD30-positive cells with an IC50 of 2.5 ng/mL. Brentuximab vedotin (solution) can be used for the research of relapsed and refractory Hodgkin lymphoma[1][2].

Product Specifications

CAS Number

[914088-09-8]

UNSPSC

12352203

Target

Antibody-Drug Conjugates (ADCs) ; Apoptosis

Type

ADC Related

Related Pathways

Antibody-drug Conjugate/ADC Related; Apoptosis

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/brentuximab-vedotin-solution.html

Purity

99.73

Solubility

10 mM in DMSO

Smiles

[Brentuximabvedotin(solution)]

Molecular Weight

153000 (average)

References & Citations

[1]Shea L, Mehta-Shah N. Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma. Curr Hematol Malig Rep. 2020 Feb;15 (1) :9-19.|[2]Francisco JA, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003 Aug 15;102 (4) :1458-65.